Azenta Acquires UK Biocentre for £20.5M to Bolster European Biorepository Footprint — Azenta, Inc.

Event summary

Azenta acquired UK Biocentre for £20.5M (net of cash), with up to £1.8M in contingent consideration tied to milestones.
UK Biocentre generated £15.3M in revenue over the 12 months ending September 30, 2025.
The acquisition is expected to be dilutive to Azenta's 2026 Adjusted EBITDA margin by ~35bps but accretive to 2027 and 2028 revenue growth and margin expansion.
UK Biocentre will operate as a European-wide hub, complementing Azenta’s existing biorepository in Griesheim, Germany.

The big picture

Azenta’s acquisition of UK Biocentre strengthens its position as a key player in Europe’s life science research ecosystem, particularly in sample storage and processing. The deal aligns with Azenta’s strategy to expand its biorepository capabilities, supporting pharmaceutical, biotech, and academic clients across the region. With increasing demand for automated, high-throughput solutions, this move could enhance Azenta’s ability to compete against other global life science service providers.

What we're watching

Integration Challenges: How Azenta will merge UK Biocentre’s operations without disrupting existing workflows or customer relationships.
Revenue Synergies: Whether the acquisition can accelerate Azenta’s revenue growth in Europe, particularly with the planned deployment of BioArc™ Ultra later this year.
Competitive Positioning: The pace at which Azenta can solidify its leadership in end-to-end sample management solutions amid rising competition in the life sciences sector.